These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20446588)

  • 1. [Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study].
    Asakura M; Kim J; Asanuma H; Kitakaze M
    Nihon Rinsho; 2010 May; 68(5):887-91. PubMed ID: 20446588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
    Hanefeld M
    Cardiovasc Diabetol; 2007 Aug; 6():20. PubMed ID: 17697384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S; Chiasson JL
    Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
    Leschke M
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis.
    Zaccardi F; Rocca B; Pitocco D; Tanese L; Rizzi A; Ghirlanda G
    Diabetes Metab Res Rev; 2015 May; 31(4):402-10. PubMed ID: 25421610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
    Roman G; Hancu N
    Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pioglitazone. Review of its metabolic and systemic effects].
    Rodríguez Bernardino A; Cebrián Blanco S; Durán García S
    Rev Clin Esp; 2005 Dec; 205(12):610-20. PubMed ID: 16527183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pioglitazone on endothelial function in impaired glucose tolerance.
    Quinn CE; Lockhart CJ; Hamilton PK; Loughrey CM; McVeigh GE
    Diabetes Obes Metab; 2010 Aug; 12(8):709-15. PubMed ID: 20590748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
    Hanefeld M; Chiasson JL; Koehler C; Henkel E; Schaper F; Temelkova-Kurktschiev T
    Stroke; 2004 May; 35(5):1073-8. PubMed ID: 15073402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral antidiabetic agents as cardiovascular drugs.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2007 Jan; 9(1):23-30. PubMed ID: 17199715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dangerous blood glucose peaks. Vascular damage even before diabetes].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584214
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes mellitus. Proceedings of a symposium. November 6-8, 2002, New York, New York, USA.
    Am J Med; 2003 Dec; 115 Suppl 8A():1S-120S. PubMed ID: 14678858
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug therapy in prediabetes.
    Mukhopadhyay P; Chowdhury S
    J Indian Med Assoc; 2005 Nov; 103(11):603-5, 608. PubMed ID: 16570765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.